Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07830225) titled 'A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma' on Sept. 15.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Rutgers, The State University of New Jersey
Condition:
Melanoma (Skin Cancer)
Intervention:
Other: A Pilot Study of ctDNA-guided immune checkpoint inhibitor duration in patients with advanced melanoma
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: September 3, 2026
Target Sample Size: 35
Countr...